
From: Michael D. Cohen <michael@mdcpc.com>
Sent: Thursday, August 24, 2017 11:42 AM
To: Jimenez, Joe
Subject: Fwd:

Joe,
As per our conversation, it appears here have been some communication with Novartis regarding the autism product...(see attached communication). Can you check to see if it was handled properly because I have seen real time video showing amazing success. I will also send you the proposal they came to your NY representative. Please let me know and I plan on being in London at the end of September so I hope to see you there.

Yours,
Michael D. Cohen, Esq.
Essential Consultants, LLC.
30 Rockefeller Plaza
23rd floor
New York, New York 10112
1-212-872-9849 (NYC Office)
1-202-457-6117 (DC Office)
[REDACTED] (Cellular)
michael@mdcpc.com

Sent from my iPhone

Begin forwarded message:

From: Michael Cohen <mdcohen212@gmail.com>
Date: August 24, 2017 at 11:36:54 AM EDT
To: michael@mdcpc.com



Michael, we spoke on 8/2 to [REDACTED] at Novartis in the US team. We reviewed the attached slides with he and a couple other colleagues who joined him on the VC. He recommended we speak to Novartis Ventures about an investment in Yamo around part of the \$5M we are seeking today. I heard from him again yesterday morning that the research and NVF team were not interested at this point. They asked that we come back to them later after our current trial data is completed. That is the contact we have had to date.

YAMO

DIAGNOSTICS